RSV vaccine using recombinant F protein ? pevion





Laboratory of Cellular Biotechnology



Iwo König, Nicole Westerfeld, Lucia Baldi, Mario Amacker, David Hacker, Christiane Zaborosch, Rinaldo Zurbriggen, Florian Wurm



RSV is a worldwide burden (64 million infections/yr, 160'000 deaths/year)

- RSV was first isolated in 1956 (Morris et al.).
- No licenced vaccine available
 - RSV weakly immunogenic
 - Enhanced disease associated with a formalin-inactivated
 - vaccine (Kapikian et al, 1969, Kim et al, 1969)

Subunit vaccine promising

F and G proteins induce neutralizing Ab (Walsh et al, 1987)

Production of recombinant RSV-F (rRSV-F) in mammalian cells by Transient Gene Expression (TGE)

Correct folding, assembly, and post-translational modifications

Scalable and simple process

Rapid and inexpensive


Production of viral RSV-F (vRSV-F) low viral titers in cell culture biosafety problems

Objectives

Establish a manufacturing process for rRSV-F :


- 1. Production of rRSV-F by transient gene expression in mammalian cells.
- 2. Scale up of the manufacturing process of rRSV-F for animal studies.
- 3. rRSV-F in virosomes : Animal experiments.

RSV-F : a trimeric membrane glycoprotein




Morton et al, 2003


Production of rRSV-F by transient gene expression – Proof of principle



Formulation of rRSV-F in virosomes - Principle



1. Production of rRSV-F by transient gene expression in mammalian cells




1. Production of rRSV-F by transient gene expression in mammalian cells

Cell line DNA amounts Transfecting agent/DNA ratio Medium for transfection Medium for production Temperature Time of harvest Addition of chemicals Expression plasmid Cell seeding density Aeration

1. Production of rRSV-F by transient gene expression in mammalian cells

Cell seeding density DNA and Transfecting Agent amounts



Optimal conditions yielded 30 mg/L of rRSV-F in 48h in HEK-293E cells.

30 mg/L at 10-mL scale ...


... Is it achievable at a larger scale ?

Disposable bioreactors:

- Single use
- Reduced crosscontamination
- Simple use
- Simplified validation
- Rapid set up
- No cleaning
- Cost-effective
- Orbital shaking




2. Scale up of the manufacturing process of rRSV-F for animal studies




12 mg of purified rRSV-F were produced for animal studies out of 1.3 L of cell culture.

3. rRSV-F in virosomes : Animal experiments



3. rRSV-F in virosomes : Animal experiments

Neutralization of RSV by BALB/c mice sera



Animal challenge in cotton rats has been performed using rRSV-F formulated in virosomes and data analysis is ongoing.

Conclusion

- 1. We developed a scalable process for the production of rRSV-F by transient gene expression in mammalian cells.
- 2. Transient gene expression allowed the rapid production of pure rRSV-F for animal studies.
- 3. rRSV-F in virosomes induces neutralizing antibodies in BALB/c mice.

Go forward with transient technology

Transient gene expression :

for animal studies



... for clinical trials ?

... for production ?

Acknowledgements



Rinaldo Zurbriggen Nicole Westerfeld Mario Amacker



Lucia Baldi David Hacker Florian Wurm Zürcher Hochschule für Angewandte Wissenschaften



Christiane Zaborosch Iwo König



Schweizerische Eidgenossenschaft Confédération suisse Confederazione Svizzera Confederaziun svizra

KTI/CTI projects